<--GAT-->

Survey Results Add to Information About ECP Treatment for CTCL

by U.S. Medicine

January 4, 2018

LEBANON, NH — Extracorporeal photopheresis (ECP) is a leukapheresis-based therapeutic procedure that has been approved by the Food and Drug Administration (FDA) for the treatment of advanced cutaneous T-cell lymphoma (CTCL) since 1988.

In ECP, white blood cells are collected and exposed to a photosensitizer, 8-methoxypsoralen (8-MOP), and ultraviolet A (UVA) radiation. UVA activates 8-MOP and causes crosslinkage of DNA. Performed via intravenous access, the procedure has three stages: (1) leukapheresis, (2) photoactivation, and (3) reinfusion of treated cell product back to the patient.

ECP, also known as extracorporeal photochemotherapy and extracorporeal photoimmunotherapy, is performed at over 200 centers worldwide. A study in the Journal of Clinical Apheresis pointed out, however, that although many apheresis centers offer ECP, little is known about current treatment practices.1

A study team led by Dartmouth-Hitchcock Medical Center researchers and including participation from the Minneapolis VAMC sought to remedy that by distributing an electronic survey to assess ECP practice internationally.

Of 251 responses, 137 met criteria for analysis. The article reports that most, 80%, of respondents were from North America. Survey responses indicated that nurses perform ECP at most centers (84%) and the majority of centers treat adults only (52%). In addition, most centers treat fewer than 50 patients/year (83%) and perform fewer than 300 procedures/year (70%).

Closed system devices (XTS and/or Cellex) are used to perform ECP at nearly all centers, 96%. Closed systems integrate drug photoactivation and reinfusion, thus lowering risk of infection, contamination, and errors during reinfusion. 

The most common indications for ECP are acute/chronic skin graft versus host disease (89%) and CTCL (63%), with a typical wait time of less than two weeks. Most centers, 66%, reported that they do not routinely perform quality control assessment of the collected product. 

The report also discussed device-specific differences in treatment parameters. “For example, XTS users more frequently have a minimum weight limit (P = 0.003) and use laboratory parameters to determine eligibility for treatment (P = 0.03),” study authors wrote. “Regardless of device used, the majority of centers assess the clinical status of the patient before each procedure.” They noted that more than 50% of respondents said they would defer treatment for hemodynamic instability due to active sepsis or heart failure, positive blood culture in the past 24 hours or current fever.

“This survey based study describes current ECP practices. Further research to provide evidence for optimal standardization of patient qualifications, procedure parameters and product quality assessment is recommended,” the researchers add.

In addition to CTCL and graft versus host disease, ECP has been shown to have efficacy in the treatment of solid organ transplant rejection, scleroderma, atopic dermatitis, epidermolysis bullosa acquisita, lichen planus, lupus erythematosus, pemphigus vulgaris, Crohn disease, and type 1 diabetes. Some researcher has suggested value of extracorporeal photopheresis in the treatment of psoriasis, rheumatoid arthritis, multiple sclerosis, nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy, and scleromyxedema. 

  1. Dunbar NM, Raval JS, Johnson A, Abikoff CM, et. al. Extracorporeal photopheresis practice patterns: An international survey by the ASFA ECP subcommittee. J Clin Apher. 2017 Aug;32(4):215-223. doi: 10.1002/jca.21486. Epub 2016 Jul 21. PubMed PMID: 27442906.

Comments are closed here.


Related Articles

Hypertension, MGUS Associated with Herbicide Exposure in Vietnam Veterans

Based on a new review, two conditions–one extremely common and the other rare–appear to be related to herbicide exposure during the Vietnam War era.

Detailed Medical History Crucial for Lung Disease Diagnosis

Both general medicine physicians and specialists can find interstitial lung disease (ILD) and pulmonary fibrosis confusing, according to a recent study.


U.S. Medicine Recommends


More From oncology

Oncology

Hypertension, MGUS Associated with Herbicide Exposure in Vietnam Veterans

Based on a new review, two conditions–one extremely common and the other rare–appear to be related to herbicide exposure during the Vietnam War era.

Oncology

Detailed Medical History Crucial for Lung Disease Diagnosis

Both general medicine physicians and specialists can find interstitial lung disease (ILD) and pulmonary fibrosis confusing, according to a recent study.

Oncology

Melanomas Associated With Internal Malignancy Risk

Genetic and environmental risk factors have been associated with the development of multiple primary melanomas (MPM) but a new study questioned whether those patients might have increased predisposition to developing internal malignancies.

Oncology

Some RCC Risk Factors Can Be Modified

Obesity, hypertension and smoking are the three modifiable risk factors that could aggressively be targeted to reduce renal cell carcinoma, according to a new study.

Oncology

Better Survival for NSCLC Patients Treated by Military Medicine

Does universal healthcare access provided by the MHS translate into improved patient outcomes for non-small cell lung cancer?

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up